Results 201 to 210 of about 247,637 (262)

Induction chemotherapy plus bevacizumab or radiotherapy in N2 non-squamous non-small cell lung cancer: 5-year results of a randomized phase 2 trial. [PDF]

JTCVS Open
Takamochi K, Suzuki K, Tsuboi M, Niho S, Ishikura S, Kobayashi S, Oyamada S, Yamaguchi T, Suzuki H, Ito H, Okumura N, Tanaka F, Saji H, Koike T, Horio H, Endo M, Fujiwara T, Ikeda N, Tanaka T, Iwata H, Haruki T, Suzuki H, Maniwa Y, Shiono S, Okada M, Advanced Clinical Trial Chest Surgery Group (ACTG).   +25 more
europepmc   +1 more source

Recent Advances in Ferrite‐Based Materials for Biomedical Applications: A Comprehensive Review

Advanced Materials, EarlyView.
Ferrite nanoplatforms are presented as tunable biomedical materials in which synthesis control, cation engineering, defect/morphology regulation, and surface functionalization govern structure–property–bioactivity relationships. These design strategies enable multifunctional applications including MRI contrast, magnetic hyperthermia, targeted drug ...
Pramod D. Mhase, Varsha C. Pujari, Akash V. Fulari, Sunil M. Patange, Sean Li, Danyang Wang, Sagar E. Shirsath   +6 more
wiley   +1 more source

Biointegrated Battery‐Based Electroceuticals

Advanced Materials, EarlyView.
Biointegrated batteries go beyond passive power to serve as active therapeutic platforms for delivering programmable electrical cues and bioactive agents. This review examines their mechanisms and applications and provides a framework to guide battery‐based therapeutic design and clinical translation.
Yan Zhou, Zhilian Yue, Zhiqi Chen, Danming Chao, Xiaoteng Jia, Gordon Wallace, Caiyun Wang   +6 more
wiley   +1 more source

PD-1 inhibitors combined with induction chemotherapy followed by chemoradiotherapy in HPV-negative locally advanced head and neck squamous cell carcinoma: a real-world study. [PDF]

Cancer Immunol Immunother
Yang Y, Wang S, Peng S, Li Y, Lei Y, Zheng W, Xu S, Huang S, Huang Y, Mao Y.   +9 more
europepmc   +1 more source

From Payload‐First Toward Dual‐Mechanism Antibody–Drug Conjugates

Advanced Materials, EarlyView.
Conjugation converts potent antibodies into underexposed carriers. This perspective defines the antibody exposure deficit and maps a mechanism‐first design space from payload‐first to antibody‐first ADC architectures, integrating DAR, linker chemistry, and Fc engineering to guide rational design of constructs that balance targeted cytotoxicity with ...
Xavier Pivot, Sebastian Jung, Sébastien Harlepp, Alexandre Detappe   +3 more
wiley   +1 more source

Evaluation of Nutritional Status During Induction Chemotherapy in Patients With Acute Leukemia. [PDF]

Cureus
Thomas S, Mahapatra M, Seth T, Viveka J.
europepmc   +1 more source

Comparison of Local Control and Toxicity in T4 Nasopharyngeal Carcinoma Patients Treated with Induction Chemotherapy and Intensity-Modulated Radiotherapy: Conventional vs. Hyperfractionated Regimens. [PDF]

Medicina (Kaunas)
Hsieh HY, Lin JC, Chang HH.
europepmc   +1 more source

Radiobiological Effects of Low-Dose Radiation in Normal Fibroblasts of Patients with Head and Neck Cancer Treated with Induction Chemotherapy Combined with Low-Dose Fractionated Radiation. [PDF]

Int J Mol Sci
Winiarska G, Rutkowski T, Gądek A, Fidyk W, Głowala-Kosińska M, Kacorzyk U, Składowski K, Słonina D.   +7 more
europepmc   +1 more source

Programmed cell death receptor 1 inhibitors combined with paclitaxel-platinum induction chemotherapy for treating patients with locally advanced nasopharyngeal carcinoma: a real-world retrospective study. [PDF]

Transl Cancer Res
Chen L, Song X, Chen J, Huang J, Gu W, Jiang W.   +5 more
europepmc   +1 more source

Neutrophil to Lymphocyte and Lymphocyte to Monocyte Ratios Predict Improved Survival and Response to Induction Chemotherapy in Locally Advanced Squamous Cell Carcinoma of the Larynx. [PDF]

Head Neck
Risch Z, Bellile E, Bughrara MS, Swiecicki PL, Casper K, Malloy K, Hogikyan N, Spector M, Shuman A, Stucken C, Chinn S, Chepeha DC, Jolly S, Mierzwa M, Bradford C, Eisbruch A, Carey T, Prince M, Wolf GT, Worden FP.   +19 more
europepmc   +1 more source